Here are five key notes:
1. The second quarter net loss attributable to common stockholders was $7.6 million, or $0.58 per share. This is lower than $11.8 million and $19.85 per share last year.
2. Research and development expenses hit $5.9 million in the second quarter, up from $4.7 million over the same period last year. There was increased activity and enrollment in the NeoCart Phase III clinical trial.
3. The company reported $45.2 million in cash, cash equivalents and marketable securities. The company believes its current cash position will fund operations into 2017.
4. There were new investigators joining the NeoCart trial last quarter, including Kaiser Permanente patients in California.
5. The company hired Jon Lieber and Gloria Mathews in the C-suite.
More articles on orthopedic devices:
SeaSpine launches Ventura NanoMetalene spine device: 5 key points
K2M, InVivo Therapeutics, Zimmer & more—19 key notes
Global sports medicine market to reach $53.6B by 2022: 6 key trends
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
